Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

A. Shah, Manish; Shitara, Kohei; A. Ajani, Jaffer; Bang, Yung‐Jue; C. Enzinger, Peter; H. Ilson, David; Lordick, Florian; Van Cutsem, Eric; Gállego, Javier; Huang, Jing; Shen, Lin; Cheul Oh, Sang; Sunpaweravong, Patrapim; Fen Soo Hoo, Hwoei; Mehmet Türk, Hacı; Oh, Mok; Wook Park, Jung; Moran, Diarmuid; Bhattacharya, Pranob; M. Arozullah, Ahsan; Xu, Rui‐Hua

doi:10.1038/s41591-023-02465-7

Public

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Published in Nature Medicine • Jul 31, 2023

Authors:

Manish A. Shah

Kohei Shitara

Jaffer A. Ajani

Abstract

There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Claudin-18 isoform 2 (CLDN18.2) is expressed in normal gastri...

Subject

Gastroesophageal Junction

Internal medicine

Gastroenterology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!